These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11677139)

  • 1. The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.
    Levin JI; Chen JM; Du MT; Nelson FC; Wehr T; DiJoseph JF; Killar LM; Skala S; Sung A; Sharr MA; Roth CE; Jin G; Cowling R; Di L; Sherman M; Xu ZB; March CJ; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2975-8. PubMed ID: 11677139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.
    Levin JI; Chen J; Du M; Hogan M; Kincaid S; Nelson FC; Venkatesan AM; Wehr T; Zask A; DiJoseph J; Killar LM; Skala S; Sung A; Sharr M; Roth C; Jin G; Cowling R; Mohler KM; Black RA; March CJ; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2189-92. PubMed ID: 11514167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.
    Levin JI; Du MT; DiJoseph JF; Killar LM; Sung A; Walter T; Sharr MA; Roth CE; Moy FJ; Powers R; Jin G; Cowling R; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Jan; 11(2):235-8. PubMed ID: 11206467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.
    Levin JI; Chen JM; Cheung K; Cole D; Crago C; Santos ED; Du X; Khafizova G; MacEwan G; Niu C; Salaski EJ; Zask A; Cummons T; Sung A; Xu J; Zhang Y; Xu W; Ayral-Kaloustian S; Jin G; Cowling R; Barone D; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2799-803. PubMed ID: 12873518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.
    Chen JM; Jin G; Sung A; Levin JI
    Bioorg Med Chem Lett; 2002 Apr; 12(8):1195-8. PubMed ID: 11934587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.
    Levin JI; Chen JM; Du MT; Nelson FC; Killar LM; Skala S; Sung A; Jin G; Cowling R; Barone D; March CJ; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2002 Apr; 12(8):1199-202. PubMed ID: 11934588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.
    Letavic MA; Barberia JT; Carty TJ; Hardink JR; Liras J; Lopresti-Morrow LL; Mitchell PG; Noe MC; Reeves LM; Snow SL; Stam EJ; Sweeney FJ; Vaughn ML; Yu CH
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3243-6. PubMed ID: 12951101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
    Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.
    Levin JI; Gu Y; Nelson FC; Zask A; DiJoseph JF; Sharr MA; Sung A; Jin G; Cowling R; Chanda P; Cosmi S; Hsiao CL; Edris W; Wilhelm J; Killar LM; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Jan; 11(2):239-42. PubMed ID: 11206468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
    Becker DP; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Munie GE; Swearingen C
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2723-5. PubMed ID: 11591510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1.
    Becker DP; Barta TE; Bedell L; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Mischke B; Munie GE; Swearingen C; Villamil CI
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2719-22. PubMed ID: 11591509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.
    Tullis JS; Laufersweiler MJ; VanRens JC; Natchus MG; Bookland RG; Almstead NG; Pikul S; De B; Hsieh LC; Janusz MJ; Branch TM; Peng SX; Jin YY; Hudlicky T; Oppong K
    Bioorg Med Chem Lett; 2001 Aug; 11(15):1975-9. PubMed ID: 11454461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
    Levin JI; Du MT
    Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and activity of selective MMP inhibitors with an aryl backbone.
    Barta TE; Becker DP; Bedell LJ; De Crescenzo GA; McDonald JJ; Munie GE; Rao S; Shieh HS; Stegeman R; Stevens AM; Villamil CI
    Bioorg Med Chem Lett; 2000 Dec; 10(24):2815-7. PubMed ID: 11133099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
    Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
    J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
    J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
    Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
    Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design strategies for the identification of MMP-13 and Tace inhibitors.
    Skotnicki JS; DiGrandi MJ; Levin JI
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Davis JM; Grosu GT; Baker J; Ellingboe J; Zask A; Levin JI; Sandanayaka VP; Du M; Skotnicki JS; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R; Tillett J; Zhao W; McDevitt J; Xu ZB
    J Med Chem; 2003 Jun; 46(12):2376-96. PubMed ID: 12773042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and identification of conformationally constrained selective MMP inhibitors.
    Freskos JN; McDonald JJ; Mischke BV; Mullins PB; Shieh HS; Stegeman RA; Stevens AM
    Bioorg Med Chem Lett; 1999 Jul; 9(13):1757-60. PubMed ID: 10406637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.